Neuralink's Blindsight Implant Receives FDA Breakthrough Device Designation
• Neuralink's Blindsight implant, designed to restore vision, has received Breakthrough Device Designation from the FDA, expediting its development and review.
• The implant aims to enable sight in individuals who have lost both eyes and their optic nerve, potentially benefiting those blind from birth.
• Early vision with Blindsight may resemble low-resolution Atari graphics, but Neuralink anticipates future enhancements, including infrared and ultraviolet vision.
• Neuralink is also developing brain implants for paralyzed individuals to control digital devices, with ongoing clinical trials evaluating their effectiveness.
© Copyright 2025. All Rights Reserved by MedPath